Sage Therapeutics (NASDAQ:SAGE) Given "Neutral" Rating at Wedbush

Sage Therapeutics (NASDAQ:SAGE - Get Free Report)'s stock had its "neutral" rating restated by equities researchers at Wedbush in a research note issued on Wednesday,Benzinga reports. They presently have a $6.00 target price on the biopharmaceutical company's stock. Wedbush's price target suggests a potential downside of 15.97% from the stock's current price.

SAGE has been the subject of a number of other reports. Piper Sandler decreased their price target on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, January 2nd. TD Cowen dropped their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating on the stock in a research report on Thursday, November 21st. StockNews.com downgraded shares of Sage Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Wednesday. Finally, Scotiabank cut their target price on shares of Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating for the company in a research note on Wednesday, October 30th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Sage Therapeutics has a consensus rating of "Hold" and an average price target of $9.65.

Sage Therapeutics Trading Down 0.6 %

Shares of NASDAQ:SAGE traded down $0.04 on Wednesday, hitting $7.14. The company's stock had a trading volume of 1,943,315 shares, compared to its average volume of 2,832,859. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $26.25. The stock's 50-day moving average is $6.40 and its two-hundred day moving average is $6.88.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. Equities analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caligan Partners LP purchased a new stake in shares of Sage Therapeutics during the fourth quarter worth $16,575,000. Jane Street Group LLC lifted its holdings in shares of Sage Therapeutics by 103.1% during the 4th quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company's stock valued at $2,509,000 after buying an additional 234,528 shares during the last quarter. PDT Partners LLC grew its stake in shares of Sage Therapeutics by 37.2% in the 4th quarter. PDT Partners LLC now owns 235,097 shares of the biopharmaceutical company's stock valued at $1,277,000 after buying an additional 63,804 shares in the last quarter. AdvisorShares Investments LLC increased its holdings in Sage Therapeutics by 104.9% in the fourth quarter. AdvisorShares Investments LLC now owns 47,800 shares of the biopharmaceutical company's stock worth $260,000 after buying an additional 24,470 shares during the last quarter. Finally, Northern Trust Corp raised its position in Sage Therapeutics by 6.0% during the fourth quarter. Northern Trust Corp now owns 524,420 shares of the biopharmaceutical company's stock valued at $2,848,000 after acquiring an additional 29,560 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.